Literature DB >> 8562294

Enantioselective disposition of hydroxychloroquine after a single oral dose of the racemate to healthy subjects.

J Ducharme1, H Fieger, M P Ducharme, S K Khalil, I W Wainer.   

Abstract

1. Stereoselectivity in the disposition of hydroxychloroquine was investigated in 23 healthy males following a single oral dose of 200 mg racemic HCQ (rac-HCQ) sulphate. Total concentrations (R+S) and R/S ratios of HCQ and its metabolites were measured by stereoselective h.p.l.c. 2. HCQ was detected in whole blood and urine, up to 91 and 85 days after dosing, respectively. Metabolites could not be detected in whole blood while in urine detectable concentrations were still present after 85 days. The blood concentrations of HCQ enantiomers were measurable until 168 h post-dose. 3. R(-)-HCQ accounted for 62 +/- 3% (mean +/- s.d.) of the AUC of rac-HCQ AUC. The elimination half-life of S(+)-HCQ (457 +/- 122 h) was significantly shorter than that of R(-)-HCQ (526 +/- 140 h), partly due to its faster urinary excretion and hepatic metabolism. Its renal clearance was twice that of R(-)-HCQ (4.61 +/- 4.01 vs 1.79 +/- 1.30 1 h-1), and metabolites derived from the S-isomer represented 80-90% of the urinary recovery of the dose. 4. Over 85 days, 4.4 +/- 2.9 and 3.3 +/- 1.8% of the dose was recovered in urine as unchanged S(+)-HCQ and R(-)-HCQ, respectively. For the first 2 weeks, S(+)-HCQ excretion rate clearly surpassed that of R(-)-HCQ whereas afterwards the inverse was observed. However, since the first 2 weeks account for 95% of rac-HCQ renal excretion, the total urinary excretion of S(+)-HCQ clearly surpassed that of R(-)-HCQ.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8562294      PMCID: PMC1365171          DOI: 10.1111/j.1365-2125.1995.tb05768.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  13 in total

Review 1.  Disease modifying drugs for rheumatoid arthritis: yesterday's treatment today or today's treatment tomorrow?

Authors:  T Pullar
Journal:  Br J Clin Pharmacol       Date:  1990-10       Impact factor: 4.335

2.  Evaluation of the methodological quality of clinical trial protocols. A preliminary experience in Spain.

Authors:  C García-Cases; A Duque; J Borja; I Izquierdo; V de la Fuente; J Torrent; F Jané
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

3.  Determination of hydroxychloroquine and its major metabolites in plasma using sequential achiral-chiral high-performance liquid chromatography.

Authors:  J Iredale; I W Wainer
Journal:  J Chromatogr       Date:  1992-01-17

4.  Concentration-effect relationship of hydroxychloroquine in rheumatoid arthritis--a cross sectional study.

Authors:  S E Tett; R O Day; D J Cutler
Journal:  J Rheumatol       Date:  1993-11       Impact factor: 4.666

5.  A dose-ranging study of the pharmacokinetics of hydroxy-chloroquine following intravenous administration to healthy volunteers.

Authors:  S E Tett; D J Cutler; R O Day; K F Brown
Journal:  Br J Clin Pharmacol       Date:  1988-09       Impact factor: 4.335

6.  Enantioselective determination of hydroxychloroquine and its major metabolites in urine and the observation of a reversal in the (+)/(-)-hydroxychloroquine ratio.

Authors:  H Fieger; J Iredale; I W Wainer
Journal:  Chirality       Date:  1993       Impact factor: 2.437

7.  Bioavailability of hydroxychloroquine tablets in healthy volunteers.

Authors:  S E Tett; D J Cutler; R O Day; K F Brown
Journal:  Br J Clin Pharmacol       Date:  1989-06       Impact factor: 4.335

8.  Disposition of the enantiomers of hydroxychloroquine in patients with rheumatoid arthritis following multiple doses of the racemate.

Authors:  A J McLachlan; S E Tett; D J Cutler; R O Day
Journal:  Br J Clin Pharmacol       Date:  1993-07       Impact factor: 4.335

9.  Stereoselective distribution of hydroxychloroquine in the rabbit following single and multiple oral doses of the racemate and the separate enantiomers.

Authors:  J Ducharme; I W Wainer; H I Parenteau; J H Rodman
Journal:  Chirality       Date:  1994       Impact factor: 2.437

10.  Animal toxicity and pharmacokinetics of hydroxychloroquine sulfate.

Authors:  E W McChesney
Journal:  Am J Med       Date:  1983-07-18       Impact factor: 4.965

View more
  14 in total

Review 1.  Bioequivalence of chiral drugs. Stereospecific versus non-stereospecific methods.

Authors:  R Mehvar; F Jamali
Journal:  Clin Pharmacokinet       Date:  1997-08       Impact factor: 6.447

Review 2.  Clinical pharmacokinetics and metabolism of chloroquine. Focus on recent advancements.

Authors:  J Ducharme; R Farinotti
Journal:  Clin Pharmacokinet       Date:  1996-10       Impact factor: 6.447

Review 3.  Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology.

Authors:  Eva Schrezenmeier; Thomas Dörner
Journal:  Nat Rev Rheumatol       Date:  2020-02-07       Impact factor: 20.543

Review 4.  Repurposing Drugs for COVID-19: Pharmacokinetics and Pharmacogenomics of Chloroquine and Hydroxychloroquine.

Authors:  Mariana Babayeva; Zvi Loewy
Journal:  Pharmgenomics Pers Med       Date:  2020-10-23

5.  Pharmacokinetics of hydroxychloroquine and its clinical implications in chemoprophylaxis against malaria caused by Plasmodium vivax.

Authors:  Hyeong-Seok Lim; Jeong-Soo Im; Joo-Youn Cho; Kyun-Seop Bae; Terry A Klein; Joon-Sup Yeom; Tae-Seon Kim; Jae-Seon Choi; In-Jin Jang; Jae-Won Park
Journal:  Antimicrob Agents Chemother       Date:  2009-02-02       Impact factor: 5.191

Review 6.  Stereoselectivity in the pharmacodynamics and pharmacokinetics of the chiral antimalarial drugs.

Authors:  Dion R Brocks; Reza Mehvar
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

7.  Effect of experimental diabetes mellitus and arthritis on the pharmacokinetics of hydroxychloroquine enantiomers in rats.

Authors:  J Emami; F M Pasutto; F Jamali
Journal:  Pharm Res       Date:  1998-06       Impact factor: 4.200

Review 8.  Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases.

Authors:  K D Rainsford; Ann L Parke; Matthew Clifford-Rashotte; W F Kean
Journal:  Inflammopharmacology       Date:  2015-08-06       Impact factor: 5.093

9.  Chiral switches of chloroquine and hydroxychloroquine: potential drugs to treat COVID-19.

Authors:  Ilaria D'Acquarica; Israel Agranat
Journal:  Drug Discov Today       Date:  2020-05-01       Impact factor: 7.851

Review 10.  Pharmacokinetics and Pharmacological Properties of Chloroquine and Hydroxychloroquine in the Context of COVID-19 Infection.

Authors:  Melanie R Nicol; Abhay Joshi; Matthew L Rizk; Philip E Sabato; Radojka M Savic; David Wesche; Jenny H Zheng; Jack Cook
Journal:  Clin Pharmacol Ther       Date:  2020-09-01       Impact factor: 6.903

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.